Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02127307 · ClinicalTrials.gov registry record

Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.

A clinical trial, sponsored by GE Healthcare.

Completed
Registry status
964
Enrollment target

NCT02127307: Completed study, sponsored by GE Healthcare.

NCT02127307 is a clinical trial that has completed, run by GE Healthcare. The registered enrollment target is 964 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02127307 has completed, sponsored by GE Healthcare.

COMPLETED
Registry status
964 participants
Enrollment target

Study Summary

This aim of the study is to investigate the prognostic usefulness of AdreView™ imaging to identify those subjects with New York Heart Association (NYHA) Class II or III HF who will die during 60 months of follow-up from the date of administration of AdreView™ in prior studies MBG311, MBG312, or MBG312C (hereafter included in MBG312).

Primary Outcome

H/M ratio for 123I-mIBG uptake at 3 hours 50 minutes post administration was calculated by dividing the counts/pixel in the total myocardium region of interest (ROI) by the counts/pixel in the 7x7 pixel mediastinal ROI. H/M ratios were categorized as 'Low' and 'High' based on being \<1.6 or ≥1.6 respectively. The efficacy of 123I-mIBG was based on the prognostic value of the imaging data, as reflected by the H/M ratio, for identifying HF participants at lower risk of death during 60 months of fo

Trial Details

FieldValue
Enrollment Target 964 participants
Start Date 2014-02
Est. Completion 2016-04
GE Healthcare

99 total trials

What the finished NCT02127307 record still lists

NCT02127307 is an observational study that tracks outcomes without assigning an intervention. The registered 964 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT02127307 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02127307 about?

NCT02127307 is a clinical study titled "Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.". This aim of the study is to investigate the prognostic usefulness of AdreView™ imaging to identify those subjects with New York Heart Association (NYHA) Class II or III HF who will die during 60 months of follow-up from the date of administration of AdreView™ in prior studies MBG311, MBG312, or MBG3...

What is the current status of trial NCT02127307?

This trial is currently completed. The enrollment target is 964 participants. The study started on 2014-02. Estimated completion is 2016-04.

Who is sponsoring clinical trial NCT02127307?

This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04726241 · 960 participants · Phase 1

    The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • NCT05142384 · 960 participants · NA

    ICBT (Internet Based Cognitive Behavioral Therapy) for Maternal Depression: Community Implementation in Head Start

  • NCT05178498 · 960 participants

    Impact of Dietary Inflammatory Potential on Breast Cancer Risk

  • NCT05946629 · 960 participants · NA

    SELUTION 4 De Novo Small Vessel IDE Trial

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02127307, the US trial registry maintained by the National Library of Medicine. NCT02127307 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.